Ventilator-associated Infection: The Role for Inhaled Antibiotics

Lucy B. Palmer


Curr Opin Pulm Med. 2015;21(3):239-249. 

In This Article


Ventilator-associated infections caused by Gram-negative MDROs are increasingly challenging to treat. As can be seen from this review, large multisite trials are needed to answer the following questions:

  1. What are the concentrations of antibiotics needed to eradicate MDROs in the proximal airway in areas of thick purulent secretion (VAT-A)?

  2. What are the best delivery devices to achieve the concentrations necessary to treat VAT and VAP?

  3. Can inhaled antibiotics reduce or eliminate systemic antibiotic use?

  4. Can inhaled therapy consistently decrease the emergence of newly resistant organisms?

The answer to these questions will determine if inhaled therapy may become one of our most effective tools for the treatment of ventilator-associated infections caused by MDROs.